Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;35(4):611-624.
doi: 10.1007/s12288-019-01085-x. Epub 2019 Jan 28.

Hematological Malignancies and Arterial Thromboembolism

Nathan Visweshwar  1 , Michael Jaglal  2 , Lubomir Sokol  2 , Benjamin Djulbegovic  3
Affiliations
Review

Hematological Malignancies and Arterial Thromboembolism

Nathan Visweshwar et al. Indian J Hematol Blood Transfus. 2019 Oct.

Abstract

Established guidelines exist for prevention and treatment of venous thromboembolism in hematological malignancies, but none for arterial thromboembolism. However, arterial and venous thromboembolism share the same provoking features-including altered procoagulant factors and defective fibrinolytic system. The morbidity for arterial thromboembolism is increasing in hematological malignancies, with the advent of immunomodulatory and targeted therapy. However, survival rate for hematological malignancy is improving. Consequently, as patients with hematological malignancies live longer, comorbidities including diabetes, hypertension and dyslipidemia, may accentuate arterial thrombosis. Thus far, the scientific literature on prophylaxis and treatment for arterial thromboembolism in hematological malignancies is limited. This review highlights the pathogenesis, incidence and clinical features of arterial thromboembolism in hematological malignancies.

Keywords: Arterial; Hematological malignancies; Thrombosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestAll authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Interaction of patient characteristics, disease characteristics and intervention in ATE of hematological malignancies
Fig. 2
Fig. 2
Interaction of endothelial dysfunction, risk factors and cytokines in hematological malignancies
Fig. 3
Fig. 3
Proposed algorithm for management of ATE in hematological malignancies
See this image and copyright information in PMC

References

    1. Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011;2011:394740. doi: 10.4061/2011/394740. - DOI - PMC - PubMed
    1. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation. 2016;133(13):1272–1289. doi: 10.1161/circulationaha.115.018347. - DOI - PMC - PubMed
    1. Li W, Cornell RF, Lenihan D, Slosky D, Jagasia M, Piazza G, et al. Cardiovascular complications of novel multiple myeloma treatments. Circulation. 2016;133(9):908–912. doi: 10.1161/circulationaha.115.018351. - DOI - PubMed
    1. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484–490. doi: 10.1200/jco.2005.03.8877. - DOI - PubMed
    1. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466–3473. doi: 10.1200/jco.2011.35.5669. - DOI - PMC - PubMed

LinkOut - more resources